Cambrex (NYSE: CBM) is one of 103 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Cambrex to similar companies based on the strength of its valuation, risk, analyst recommendations, dividends, profitability, earnings and institutional ownership.
This is a breakdown of recent ratings and target prices for Cambrex and its rivals, as reported by MarketBeat.
||Strong Buy Ratings
Cambrex currently has a consensus price target of $62.33, suggesting a potential upside of 20.68%. As a group, “Pharmaceuticals” companies have a potential upside of 18.89%. Given Cambrex’s stronger consensus rating and higher possible upside, analysts clearly believe Cambrex is more favorable than its rivals.
Institutional and Insider Ownership
43.9% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 2.5% of Cambrex shares are owned by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Cambrex has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Comparatively, Cambrex’s rivals have a beta of 0.92, indicating that their average stock price is 8% less volatile than the S&P 500.
Valuation & Earnings
This table compares Cambrex and its rivals top-line revenue, earnings per share (EPS) and valuation.
Cambrex’s rivals have higher revenue and earnings than Cambrex. Cambrex is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Cambrex and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Cambrex beats its rivals on 7 of the 13 factors compared.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.